The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients

Blood. 2020 May 21;135(21):1912-1915. doi: 10.1182/blood.2020006288.
No abstract available

MeSH terms

  • Agammaglobulinaemia Tyrosine Kinase / antagonists & inhibitors
  • Aged
  • Betacoronavirus / isolation & purification*
  • COVID-19
  • Coronavirus Infections / complications
  • Coronavirus Infections / drug therapy*
  • Female
  • Humans
  • Lung Injury / prevention & control*
  • Male
  • Middle Aged
  • Pandemics
  • Pneumonia, Viral / complications
  • Pneumonia, Viral / drug therapy*
  • Protein Kinase Inhibitors / administration & dosage
  • Protein Kinase Inhibitors / therapeutic use*
  • Pyrazoles / administration & dosage
  • Pyrazoles / therapeutic use*
  • Pyrimidines / administration & dosage
  • Pyrimidines / therapeutic use*
  • SARS-CoV-2
  • Waldenstrom Macroglobulinemia / complications
  • Waldenstrom Macroglobulinemia / drug therapy*

Substances

  • Protein Kinase Inhibitors
  • Pyrazoles
  • Pyrimidines
  • ibrutinib
  • Agammaglobulinaemia Tyrosine Kinase
  • BTK protein, human